U.S. health officials are alerting consumers about two more recalls of eyedrops due to contamination risks that could lead to vision problems and serious injury.

The announcements follow a recall last month of eyedrops made in India that were linked to an outbreak of drug-resistant infections. One person died and at least five others had permanent vision loss.

There's no indication the latest recalls are related to those products.

The Food and Drug Administration posted separate recall notices for certain eyedrops distributed by Pharmedica and Apotex after the companies said they are voluntarily pulling several lots of their products from the market. Both companies said the recalls were conducted in consultation with the FDA.

Pharmedica on Friday said it is recalling two lots of Purely Soothing 15% MSM Drops due to problems “that could result in blindness." The over-the-counter drops are designed to treat eye irritation. The Phoenix-based company said consumers should immediately stop using the drops and return them to the place they were purchased.

The recall affects nearly 2,900 bottles, according to the company. The drops were manufactured in Arizona.

Last week, the FDA posted a separate recall announcement from Apotex recalling six lots of prescription eyedrops used to treat a form of glaucoma. The company said it launched the recall after finding cracks in a handful of bottle caps.

The drops are distributed as Brimonidine Tartrate Ophthalmic Solution. 0.15% and were sold between last April through February.

Apotex said in an email that the eyedrops were manufactured in Canada. The company hasn't received any reports of injuries related to the drops.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Share:
More In Science
Bill Gates-Backed Verdox on Pioneering Low-Cost Carbon Capture Tech
The Bill Gates-founded Breakthrough Energy company invested $80 million in Verdox Inc. to facilitate efficient, lower-cost technolog to remove carbon from the air and emission sources. CEO of Verdox, Brian Baynes, joined Cheddar News to discuss the investment, how the company's tech works, and where he sees it going. "We anticipate that with technologies like ours, we potentially can get to the scale of about a million tons per year within 5-10 years," he said. "And then ultimately we need to be doing this at the scales of billions of tons per year and ultimately about 10 billion tons per year in the year 2050."
Fears Ukraine War Could Lead to Rise in COVID-19, Other Infectious Diseases
As the Russia's invasion of Ukraine continues, medical experts are worried conditions in active warzones will exacerbate the current pandemic — or even give rise to other contagions. Dr. Daniel Fagbuyi, a war veteran and former Obama administration biodefense appointee, joined Cheddar News to discuss the ongoing danger of COVID-19 on top of the war, as well as the potential for new variants to emerge. "I mean just large volumes of people definitely is a breeding ground. That's the worst case," he said. "Two things don't mix: war-conflict and a virus, a potential pandemic virus."
Medical Cannabis Company Akanda Sees Stock Surge in March's First IPO
Medical cannabis company Akanda went public this week in what was the first traditional IPO of the month. Shares jumped about 163% in the stock's first day of trading. The London-based company says it hopes to supply medical cannabis products to wholesalers in international markets. Tej Virk, CEO of Akanda, joins Cheddar News' Closing Bell to discuss.
Colossal CEO Says Its About Saving Biodiversity, Not Just Extinct Woolly Mammoth
Bioscience and genetic engineering company, Colossal, raised $60 million in a Series A funding round. Colossal is focused on developing new technologies and genetic tools to restore extinct species, and protect critically endangered species. One of the startup's long-term goals is to resurrect the woolly mammoth, and return it back to the arctic. Colossal also says it is developing technology that expands beyond animals, and has the potential to advance human health. Ben Lamm, co-founder and CEO of Colossal, joins Cheddar News' Closing Bell to discuss.
Load More